Basic Information
| LncRNA/CircRNA Name | uc.134 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RIP etc. |
| Sample | hepatocellular carcinoma tissues |
| Expression Pattern | down-regulated |
| Function Description | he ISH assay revealed that uc.134 expression was significantly decreased in 170 paraffin-embedded samples from patients with HCC compared with adjacent tissues and uc.134 expression directly correlated with patient prognosis. |
| Pubmed ID | 28420424 |
| Year | 2017 |
| Title | A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1 |
External Links
| Links for uc.134 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |